2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

Solid cancer cells

" in MedChemExpress (MCE) Product Catalog:

84

Inhibitors & Agonists

1

Fluorescent Dye

4

Biochemical Assay Reagents

4

Peptides

28

Inhibitory Antibodies

3

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146999
    YM458

    		Histone Methyltransferase Epigenetic Reader Domain Apoptosis Cancer
    YM458 is a potent EZH2 and BRD4 dual inhibitor with IC50s of 490 nM and 34 nM, respectively. YM458 inhibits cell proliferation and colony formation and induces cell cycle arrest and apoptosis in solid cancer cells. YM458 can be used for researching anticancer .
    YM458
  • HY-N2732
    6-Prenylapigenin

    6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin

    		 Others Cancer
    6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells .
    6-Prenylapigenin
  • HY-164493
    KRASG12C IN-13

    		Ras Cancer
    KRASG12C IN-13 (LY3499446) is a potent KRAS G12C inhibitor. KRASG12C IN-13 is promising for research of advanced solid tumors including non-small cell lung cancer and colorectal cancer .
    KRASG12C IN-13
  • HY-P991397
    Sym023

    		Tim3 Cancer
    Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
    Sym023
  • HY-P991423
    MEDI0639

    21H3RK

    		 Notch Cancer
    MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
    MEDI0639
  • HY-176761
    Apoptotic agent-6

    		Apoptosis Cancer
    Apoptotic agent-6 (NSC-647889) is an apoptotic agent. Apoptotic agent-6 potently induces apoptotic for vulticellular spheroids (MCS) of the periphery cells. Apoptotic agent-6 can be used for solid cancer tumors research, particularly adisseminated solid tumors .
    Apoptotic agent-6
  • HY-P10841
    CyPep-1

    		Amino Acid Derivatives Cancer
    CyPep-1 is a novel cationic lytic peptide with antitumor activity. CyPep-1 is highly cytotoxic by interacting with the negatively charged cell membrane of cancer cells. CyPep-1 has strong cytolytic activity on cancer cells both in vivo and in vitro, and can be used in the study of solid tumors .
    CyPep-1
  • HY-P991540
    AT008

    		CCR Cancer
    AT008 is an anti-GPCR monoclonal antibody that blocks the binding of chemokine ligands to its cell surface receptor CCR4. AT008 can be studied in research for certain haematological and solid cancers.
    AT008
  • HY-P991244
    REGN-1400

    		EGFR Cancer
    REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
    REGN-1400
  • HY-139453A
    LP-284

    		DNA Alkylator/Crosslinker Cancer
    LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .
    LP-284
  • HY-P99517
    Voxalatamab

    JNJ-63898081; JNJ-081

    		 CD3 PSMA Cancer
    Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
    Voxalatamab
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-P991344
    AMP-224

    		PD-1/PD-L1 Cancer
    AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .
    AMP-224
  • HY-Z8644
    N-Deacetyl-N-formylcolchicine

    N-Formyl-N-deacetylcolchicine

    		 Microtubule/Tubulin Cancer
    N-Deacetyl-N-formylcolchicine (N-Formyl-N-deacetylcolchicine, Compound 11) is a selective inhibitor targeting the colchicine-binding site of tubulin. N-Deacetyl-N-formylcolchicine shows antiproliferative activity against various cancer cell lines with IC50 values of 32.61-100.28 nM. N-Deacetyl-N-formylcolchicine inhibits microtubule polymerization to block cell division, induces cancer cell apoptosis and suppresses migration. N-Deacetyl-N-formylcolchicine is promising for research of cancers such as lung cancer and various solid tumors .
    N-Deacetyl-N-formylcolchicine
  • HY-162763
    FLQY2

    		Apoptosis Cancer
    FLQY2 is a camptothecin analog that exhibits outstanding antitumor efficacy against various solid tumors. FLQY2 possesses both in vitro and in vivo anti-pancreatic cancer activity, inhibiting cell proliferation, colony formation, inducing apoptosis, and causing cell cycle arrest at nanomolar concentrations .
    FLQY2
  • HY-W013122
    Cholesteryl n-butyrate

    Cholesteryl butyrate

    		 Biochemical Assay Reagents Cancer
    Cholesteryl n-butyrate is a cholesterol ester composed of cholesterol and butyrate, two naturally occurring substances. Cholesteryl n-butyrate can be used to synthesize solid lipid nanoparticles (SLNs) with inhibitory activity on the adhesion and migration of colon cancer cells, providing a delivery system for the anticancer drug butyrate .
    Cholesteryl n-butyrate
  • HY-157231A
    HC-5404-Fu

    		PERK Cancer
    HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .
    HC-5404-Fu
  • HY-P991216
    ERY-974

    		Glycoprotein VI Apoptosis Cancer
    ERY-974 is a T-cell-engaging bispecific antibody (TCB) targeting GPC3. ERY-974 binds to both GPC3 and the CD3 receptor on T cells simultaneously, activating T cells and prompting them to release perforin and granzyme, triggering apoptosis of tumor cells. ERY-974 is promising for research of solid tumors, such as liver cancer .
    ERY-974
  • HY-P991612
    S095024

    Sym024

    		 CD73 Inflammation/Immunology Cancer
    S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
    S095024
  • HY-P10762
    Ricorfotide vedotin

    CBP-1008; LDC 10B

    		 Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    Ricorfotide vedotin
  • HY-P99827
    Cobolimab

    TSR-022; GSK4069889

    		 Tim3 Cancer
    Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
    Cobolimab
  • HY-172663A
    Trabectedin derivative 1 TFA

    		DNA/RNA Synthesis Apoptosis Cancer
    Trabectedin derivative 1 TFA is a selective DNA minor groove binder. Trabectedin derivative 1 TFA inhibits DNA transcription and repair to induce tumor cell apoptosis. Trabectedin derivative 1 TFA is promising for research of solid tumors such as soft tissue sarcoma and ovarian cancer .
    Trabectedin derivative 1 TFA
  • HY-155163
    APG-2449

    		Anaplastic lymphoma kinase (ALK) ROS Kinase FAK Apoptosis Cancer
    APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies .
    APG-2449
  • HY-157990
    Wnt/β-catenin-IN-1

    		Wnt β-catenin Cancer
    Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .
    Wnt/β-catenin-IN-1
  • HY-177134
    Taligantinib

    		VEGFR c-Met/HGFR Cancer
    Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
    Taligantinib
  • HY-168022
    CAM2602

    		Aurora Kinase Cancer
    CAM2602 is an Aurora A-TPX2 interaction inhibitor that has a binding affinity of 19 nM to Aurora A. CAM2602 can inhibit the growth of pancreatic cancer cells. In solid tumor transplant models, CAM2602 can increase the proportion of PH3 positive cells while reducing the proportion of P-Thr288 Aurora A positive cells, thereby inhibiting tumor growth .
    CAM2602
  • HY-P99422
    Adebrelimab

    SHR-1316

    		 PD-1/PD-L1 Apoptosis Cancer
    Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
    Adebrelimab
  • HY-101991
    ML291

    		PERK Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    ML291 is a UPR (unfolded protein response)-inducing sulfonamidebenzamide. ML291 overwhelms the adaptive capacity of the UPR and induces apoptosis in a variety of solid cancer models. ML291 can activate the PERK/eIF2a/CHOP (apoptotic) arm of the UPR and reduce leukemic cell burden .
    ML291
  • HY-N2424
    Flavone

    2-Phenyl-4-chromone

    		 CDK Apoptosis Caspase Cancer
    Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .
    Flavone
  • HY-P991588
    HLX-22

    AC101

    		 EGFR Cancer
    HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
    HLX-22
  • HY-123656
    Antiproliferative agent-61

    		Apoptosis Cancer
    Antiproliferative agent-61 is a synthetic β-carlinyl chalcone with significant antiproliferative activity. Antiproliferative agent-61 showed significant effects in a range of solid tumor cell lines, with the most prominent effects in breast cancer. Antiproliferative agent-61 showed IC50 values of 2.25 and 3.29 μM in the human breast cancer MCF-7 cell line. Antiproliferative agent-61 significantly induced DNA fragmentation and apoptosis in breast cancer cells. Antiproliferative agent-61 inhibited the interaction of MDM2 with p53 and promoted the degradation of MDM2 .
    Antiproliferative agent-61
  • HY-W848341
    Clomesone

    NSC 338947; CIEtSoSo

    		 DNA Alkylator/Crosslinker Cancer
    Clomesone (NSC 338947) is a compound with antitumor activity. Clomesone induces the formation of cross-links between DNA strands in cell lines. Clomesone is inactive against most human colorectal cancer solid tumor cell lines in vitro, has no significant activity against mouse tumors in vivo, and is accompanied by bone marrow suppression. Its pharmacokinetic behavior indicates that it cannot reach effective concentrations at the tumor site.
    Clomesone
  • HY-P99291
    Etaracizumab

    LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody

    		 Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Etaracizumab
  • HY-172769
    CM112

    		Histone Methyltransferase Cancer
    CM112 is a selective protein arginine methyltransferase 1 (PRMT1) degrader by tethering hydrophobic tag, adamantane, to MS023 with a 5-PEG linker. CM112 induces the degradation of PRMT1 in various solid cancer cell lines. CM112 can also target the nonenzymatic function of PRMT1 by downregulating the stability of the orphan receptor TR3. CM112 is promising for research of cancers .
    CM112
  • HY-158618
    Aurora kinase inhibitor-14

    		Aurora Kinase Apoptosis Cancer
    Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .
    Aurora kinase inhibitor-14
  • HY-P991537
    HS-20093 Antibody

    GSK5764227

    		 Antibody-Drug Conjugates (ADCs) CD276/B7-H3 Cancer
    HS-20093 Antibody is an antibody-drug conjugate (ADC) targeting B7-H3. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .
    HS-20093 Antibody
  • HY-15205
    Ganetespib
    Maximum Cited Publications
    35 Publications Verification

    STA-9090

    		 HSP Apoptosis Cancer
    Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3 .
    Ganetespib
  • HY-P10928A
    BCY17901

    		Transferrin Receptor Neurological Disease Cancer
    BCY17901 is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
    BCY17901
  • HY-164129
    CDK4-IN-3

    		CDK Apoptosis Cancer
    CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC50=25 nM, >10-fold selective over CDK6). CDK4-IN-3 arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK4-IN-3 is promising for research of solid tumors such as breast and lung cancers .
    CDK4-IN-3
  • HY-P99406A
    Petosemtamab (FUT8-KO)

    		EGFR Cancer
    Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
    Petosemtamab (FUT8-KO)
  • HY-P10928
    BCY17901 TFA

    		Transferrin Receptor Neurological Disease Cancer
    BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
    BCY17901 TFA
  • HY-162858
    BRD-810

    		Caspase Cancer
    BRD-810 is a highly selective MCL1 inhibitor. BRD-810 can bind to the BH3 groove of MCL1 and block the sequestration of pro-apoptotic proteins, quickly inducing caspase activation in MCL1-dependent cell lines. BRD-810 shows anti-tumor activity in models of blood cancers and solid tumors .
    BRD-810
  • HY-16160
    Cysmethynil

    		Autophagy ICMT Cancer
    Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
    Cysmethynil
  • HY-159642G
    TYRA-300

    		FGFR Cancer
    TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for FGFR3 with an IC50 of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .
    TYRA-300
  • HY-P991510
    CDX-1140

    		TNF Receptor Cancer
    CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
    CDX-1140
  • HY-122844B
    Ifebemtinib tosylate

    BI-853520 tosylate; IN-10018 tosylate

    		 FAK Cancer
    Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma .
    Ifebemtinib tosylate
  • HY-113217
    Cholesteryl oleate

    		Liposome Endogenous Metabolite Metabolic Disease Cancer
    Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing .
    Cholesteryl oleate
  • HY-P99667
    Ipafricept
    2 Publications Verification

    OMP-54F28; FZD8-Fc

    		 Wnt Cancer
    Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
    Ipafricept
  • HY-18957C
    Lifirafenib hydrochloride

    BGB-283 hydrochloride

    		 Endogenous Metabolite Cancer
    Lifirafenib hydrochloride (BGB-283 hydrochloride) is a novel, reversible B-RAFV600E inhibitor with antitumor activity. Lifirafenib has shown potent antitumor activity against solid tumors with B-RAFV600E mutations, such as melanoma, thyroid cancer, and low-grade serous ovarian cancer. Lifirafenib exhibits selective cytotoxicity in vitro, preferentially inhibiting the proliferation of cancer cells with B-RAFV600E and EGFR mutations/amplification. Lifirafenib can achieve dose-dependent inhibition of tumor growth in animal models, accompanied by partial and complete tumor shrinkage .
    Lifirafenib hydrochloride
  • HY-P991582
    BI-1607

    		Fc Receptor (FcR) Cancer
    BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
    BI-1607

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: